WASHINGTON - Proposals for streamlined procedures for human gene therapy protocols, eliminating overlap between the NIH's Recombinant DNA Advisory Committee and the FDA, will be discussed at the RAC's meeting on Sept. 12-13.
The proposals, published last week in the Federal Register, emanate from a July meeting of the National Task Force on AIDS Drug Development, which was held to indentify barriers to AIDS drug discovery. Task Force